Home Compare ALC.SW vs JAZZ
Stock Comparison · Structural lead, mixed market

Alcon vs Jazz Pharmaceuticals: Which Stock Looks Stronger in 2026?

Jazz Pharmaceuticals holds the cleaner structural position, with valuation as the main driver and profitability adding further support. Alcon does not offset that deficit through any equally strong structural edge elsewhere. On the market side, Jazz Pharmaceuticals is in better shape — its trend is intact while Alcon's trend has broken down. That puts structure and market broadly in agreement — Jazz Pharmaceuticals's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest score difference appears in valuation. The overall score gap is 23 points in favour of Jazz Pharmaceuticals plc.

Trajectory Similarity
0.50
Loose match
Peer-set rank: #10
within Alcon Inc.'s functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

The pair still fits the compare framework, though the long-term structural overlap is relatively light.

The strongest overlap appears in revenue stability and investment intensity.

Similarity drivers
revenue stabilityinvestment intensity
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
ALC.SW
Alcon Inc.
33
Peer-Score
Signal qualityHigh
vs
JAZZ
Jazz Pharmaceuticals plc
56
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: ALC.SW vs JAZZ Profitability 21 35 Stability 47 44 Valuation 33 88 Growth 38 48 ALC.SW JAZZ
Gap Ranking
#1 Valuation +55
#2 Profitability +14
#3 Growth +10
#4 Stability +3
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ALC.SW and JAZZ Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ALC.SWJAZZ Relative valuation Structural strength

The two profiles are relatively close, but the price setup still leans toward Jazz Pharmaceuticals plc.

Valuation position uses peer-relative PE percentile (idx_pct_pe) and Forward P/E where available.

Relative Position vs Comparable Companies
Valuation
On valuation, Jazz Pharmaceuticals plc ranks near the top of the group; Alcon Inc. sits in the weaker half.
Profitability
Neither side looks especially strong on profitability, though Jazz Pharmaceuticals plc still ranks somewhat higher.
Valuation — Dominant Gap
ALC.SW
33
JAZZ
88
Gap+55in favour of JAZZ

The multiple-based pricing edge comes from a forward P/E that is 9.9 turns lower.

What keeps the gap from being one-sided

Stability is the one area where Alcon Inc. still pushes back materially — it is the steadier name on this dimension, which keeps the result from reading as one-way.

What this means for the comparison

Valuation is the clearest driver, and profitability also supports Jazz Pharmaceuticals plc's broader structural position.

Explore full peer positioning in AssetNext

Break down the ALC.SW vs JAZZ comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-driven comparisons

Explore how ALC.SW and JAZZ each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.